News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
Pfizer Inc. Heart-Failure Drug, Inspra Helps Milder Patients
November 15, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
CHICAGO (Reuters) - People with mild heart failure lived longer and fared better by adding Pfizer's drug Inspra to standard medications, a finding that could widely expand use of such drugs in healthier patients, researchers said on Sunday.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
Postmarket research
MORE ON THIS TOPIC
Immunology and inflammation
Zenas Plummets After Late-Stage Data Fall Short of Amgen in Inflammatory Disease
January 6, 2026
·
2 min read
·
Tristan Manalac
Weight Loss
Lilly’s Path to $94B in Revenue Rests on Oral Obesity Market and Other 2026 Milestones
January 5, 2026
·
3 min read
·
Annalee Armstrong
Immunology and inflammation
J&J Stops Mid-stage Eczema Trial as $1.25B Asset Misses Efficacy Mark
January 5, 2026
·
2 min read
·
Nick Paul Taylor
IN PARTNERSHIP WITH TAKEDA
Takeda’s Commitment to Trial Representation is Shaping the Future of Clinical Research
January 5, 2026
·
5 min read
·
BioSpace Insights
